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Objectives: In 2014 probiotic supplementation (Lactobacillus acidophilus and
Bifidobacterium longum subspecies infantis; Infloranr) was introduced as standard of
care to prevent necrotizing enterocolitis (NEC) in extremely preterm infants in Norway.
We aimed to evaluate the influence of probiotics and antibiotic therapy on the developing
gut microbiota and antibiotic resistome in extremely preterm infants, and to compare with
very preterm infants and term infants not given probiotics.
Study design: A prospective, observational multicenter study in six tertiary-care
neonatal units. We enrolled 76 infants; 31 probiotic-supplemented extremely preterm
infants <28 weeks gestation, 35 very preterm infants 28–31 weeks gestation not given
probiotics and 10 healthy full-term control infants. Taxonomic composition and collection
of antibiotic resistance genes (resistome) in fecal samples, collected at 7 and 28 days
and 4 months age, were analyzed using shotgun-metagenome sequencing.
Results: Median (IQR) birth weight was 835 (680–945) g and 1,290 (1,150–1,445) g
in preterm infants exposed and not exposed to probiotics, respectively. Two extremely
preterm infants receiving probiotic developed NEC requiring surgery. At 7 days of age we
found higher median relative abundance of Bifidobacterium in probiotic supplemented
infants (64.7%) compared to non-supplemented preterm infants (0.0%) and term control
infants (43.9%). Lactobacillus was only detected in small amounts in all groups, but
the relative abundance increased up to 4 months. Extremely preterm infants receiving
probiotics had also much higher antibiotic exposure, still overall microbial diversity and
resistome was not different than in more mature infants at 4 weeks and 4 months.
Esaiassen et al. Probiotics to Preterm Infants
Conclusion: Probiotic supplementation may induce colonization resistance and
alleviate harmful effects of antibiotics on the gut microbiota and antibiotic resistome.
Clinical Trial Registration: Clinicaltrials.gov: NCT02197468. https://clinicaltrials.gov/
ct2/show/NCT02197468
Keywords: gut microbiota, preterm infant, shotgun metagenome sequencing, taxonomy, bifidobacteria,
lactobacilli, colonization resistance
INTRODUCTION
Preterm infants experience unique challenges in
establishing their gut microbiota. Cesarean deliveries, extensive
antenatal, and neonatal antibiotic exposure, parenteral nutrition
and residing for long periods in a neonatal intensive care
unit (NICU), may cause unpredictable perturbations of the
gut microbiota development (1). Gut microbiota dysbiosis
in the first weeks of life is associated with perturbations of
the developing immune system (2), and an increased risk of
necrotizing enterocolitis (NEC) (3). Probiotic supplementation
aims to restore the gut microbiota, and thereby preventing NEC
and other complications (4–6). Meta-analyses of randomized
and observational trials show that probiotic supplementation,
mainly with bifidobacteria and/or lactobacilli, reduce rates
of NEC (4, 5, 7, 8). The effects seem to be strain-specific (5)
and not all products are efficacious (9). Still, based on recent
evidence (4, 10) and expert opinion (11), many NICUs in
Europe, Australia, and Canada have implemented routine
probiotic-supplementation to preterm infants. Probiotics are
infrequently used in preterm infants in the USA (12). Risks of
probiotic sepsis and contaminations of probiotic products may
explain skepticism (13–16). Some experts recommend waiting
for additional studies to confirm the safety and efficacy of an
available and reliable product (17). Moreover, there is a paucity
of in-depth knowledge on microbiological effects and effective
dose of probiotic therapy.
Antibiotics are the most commonly prescribed medications
in the NICU (18), and prolonged therapy increases the risk of
NEC (19, 20). Antibiotics may influence both the physiological
gut microbiota composition and the collection of antibiotic
resistance genes (ARGs) in the gut, defined as the gut antibiotic
resistome (21, 22). However, there is limited knowledge on how
probiotic supplementation and antibiotic therapy influence the
gut antibiotic resistome in extremely preterm infants.
In Norway probiotic supplementation was implemented as
standard of care for extremely preterm infants in 2014. In
a longitudinal multi-center study, using shotgun-metagenomic
sequencing, we set out to evaluate the influence of probiotics
and antibiotic therapy on the developing gut microbiota and
antibiotic resistome in extremely preterm infants supplemented
Abbreviations: ARG, Antibiotic resistance genes; CARD, Comprehensive
antibiotic resistance database; CFU, Colony forming units; FDR, False discovery
rate; FTC, Full-term control; NEC, Necrotizing enterocolitis; NICU, Neonatal
intensive care unit; NMDS, Non-metrical multidimensional scaling; NVPVP,
Non-probiotic very preterm; PEP, Probiotic extremely preterm.
with probiotics. We also compared these results to very preterm
infants not supplemented with probiotics and a group of healthy,
full-term infants.
MATERIALS AND METHODS
Study Patients and Sampling Procedure
We prospectively planned to include two convenient groups
of preterm infants from six Norwegian NICUs; one group
of extremely preterm infants (gestational age 25–27 weeks)
supplemented with probiotics, and one group of very preterm
infants (gestational age 28–31 weeks) not supplemented with
probiotics. Exclusion criteria were gestation below 25 weeks
and/or an early, life threatening condition leading to high risk
of not surviving the first weeks of life. We included a control
group of 10 healthy, vaginally delivered full-term control (FTC)
infants born at the University Hospital of Northern Norway.
Sample size calculation for studies assessing gut microbiota
taxonomic composition can be performed by assessing matrices
of pairwise distances between groups (23). We expected that
around 30 infants in each group of preterm infants would afford
90% statistical power to detect differences in gut microbiota
composition that were smaller than effects previously observed
in microbiota studies of antibiotic exposure (23). The sample
size was also adapted to cover the high expenses for shotgun-
metagenome sequencing. The original protocol (24) focused on
taxonomic composition. We decided post hoc to add a resistome
analysis.
After careful instructions, fecal samples were collected by
a nurse in the NICU at around seven and 28 days of age,
and by the parents at home at around 4 months of age. We
used a commercially available sampling kit (OMNIgen GUT kit,
DNA Genotek, Ottawa, Canada) allowing storage of samples at
ambient temperatures for up to 14 days before DNA extraction
(25). We obtained routine clinical data including details on
antibiotic exposure. NEC was defined as Bell’s stage 2–3 (26).
DNA Extraction, Library Preparation, and
Sequencing
Total metagenomic DNA was extracted using the NorDiag
Arrow Stool DNA Extraction kit (NorDiag, Oslo, Norway).
An extra beadbeating step was added to facilitate cell lysis
as studies have shown that this can increase extraction of
DNA from Gram-positive bacteria. DNA was quantified using
the Nanodrop 1000 and Qubit R© 2.0 Fluorometer (Invitrogen,
Carlsbad, CA, USA) along with the Qubitr dsDNA HR assay
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kit (Thermo Fisher Scientific, Waltham, MA, USA). DNA was
then stored at −70◦C. The indexed paired-end libraries were
prepared for whole genome sequencing using the Nextera XT Kit
(Illumina, San Diego, CA, USA), according to the manufacturer’s
instructions. Fifty nanograms of genomic DNA was tagmented
at 55◦C for 10min. The tagmented DNA was amplified with
two primers from Nextera DNA sample preparation Index Kit.
PCR products were cleaned using Agencourt AMPure XP beads
(Beckman Coulter, Indiana, USA). Purified PCR products were
quantified using the Qubitr 2.0 (Invitrogen, Carlsbad, CA,
USA), along with the Qubitr dsDNA HS assay kit (Thermo
Fisher Scientific, Waltham, MA, USA). The fragment size
distribution (500–1,000 bp) was analyzed using the Agilent
2100 Bioanalyzer System (Agilent Technologies, Waldbronn,
Germany). The samples were pooled at concentration of 4 nMper
sample. Eight to twelve samples were pooled per each sequencing
run. Pooled samples was denatured with 0.2N NaOH, then
diluted to 10 pM with hybridization buffer. Subsequently,
samples were submitted for v3 reagents with 2 × 300 cycles
paired-end sequencing using the Illumina Miseq platform,
according to the manufacturer’s instructions. In total, 184
samples were sequenced to an average (range) sequence depth of
4.8 (1.8–12.6) million reads per sample for microbiota and
functional analysis. Prior to all downstream data analysis,
the sequence quality was calculated using FastQC (v0.11.3).
All samples were screened for human contamination using
Deconseq with default parameters and build up 38 of the human
genome as reference. Quality filtering of the read was performed
using Trimmomatic v0.36 with LEADING:3, TRAILING:3,
MINLEN:75 as parameter settings. Assemblies were performed
on the trimmed reads using MEGAHIT. Functional annotation
was added using an in-house genome annotation pipeline, the
META-pipe (Department of Chemistry, University of Tromsø,
Norway [https://arxiv.org/abs/1604.04103]). The sequences are
deposited in the European Nucleotide Archive (www.ebi.ac.uk/
ena); study accession nr. PRJEB29052.
Taxonomic Profiling
The relative abundance of bacteria at genus level was calculated
from the trimmed reads using MetaPhlAn 2.0 (27). Relative
abundance tables for each individual sample were merged. To
calculate longitudinal changes, sequences were reconstructed
using the Lowest Common Ancestor (LCA) classifier.
The Gut Antibiotic Resistome
The prediction of genes presumed to confer antibiotic resistance
was performed on the assembled metagenomes using Abricate
[https://github.com/tseemann/abricate] against the resistance
gene identifier in the Comprehensive Antibiotic Resistance
Database (CARD; version 1.1.1; Dept. of Biochemistry and
Biomedical Science, McMaster University, Canada, https://
card.mcmaster.ca/home]) (25–28) with the minimum identity
threshold set to 75% (28). Because of the fragmented nature of the
metagenome assemblies, and therefore presence of fragmented
genes, multiple hits against the same antibiotic resistance
gene (ARG) were regarded as one hit. Data are presented as
distribution of ARG classes among the three different groups of
infants at three time points. Classes of antibiotic resistance genes
in the CARD database and the specific genes included in each
class are listed below
• Beta lactamase: blaMIR, blaZ, blaACT, blaTEM, blaCMY,
blaLEN, blaADC, blaACI, blaOXA, blaOXY, blaSHV, blaDHA,
blaOKP, blaACC, blaSED, blaMOR, blaCMG, blaCFE, cfiA,
cepA, cfxA
• Methicillin resistance:mecA
• Aminoglycosides: aac(6′)-aph(2), aac(6′)-Ic, aac(6′)-Im, aadA,
aadB, aadD, aadE, ant(6)-Ia, aph(2)-Ib, aph(3)-Ia, aph(3)-III,
spc, str, strA,strB
• Tetracyclines: tet(A), tet(B), tet(M), tet(K), tet(X), tet(O), tet(L),
tet(U), tet(Q), tet(W), tet(S), tet(32), tet(34), tet(35), tet(37),
tet(40), tet(41), Otr(A)
• Fluoroquinolones: QnrB, QnrD
• MLS: Macrolide: erm(A), erm(B), erm(C), erm(F),erm(G),
erm(T), erm(X), mph(A), mph(C); Lincosamide: lnu(B), lnu(C);
Streptogranin: vat(B), vat(F)
• ABC efflux: lsa(A),lsa(B), lsa(C), msr(A), mrs(C), msr(D),
ole(B), car(A)
• RND efflux pumps: oqxA
• Efflux pumps: vga(A), mef(A)
• Multidrug efflux pumps: norA
• Chloramphenicol: cat, catA, catB, catS, cmlA, cml
• Fosfomycin: fos(A)
• Sulfonamides: sul1, sul2
• Antibiotic target: dfrA, dfrG
• Vancomycin: VanC, VanS, VanT, VanR, VanY
• Metronidazole: nimB
In order to obtain quantitative measures of the putative ARGs
in each sample, the quality trimmed reads were analyzed using
Short, Better Representative Extract Dataset (ShortBRED) (29)
against a formatted CARD database and normalized per total
reads in each sample. Data are presented as abundance of ARGs
among the three different groups of infants at three time points.
Using ShortBRED we identified the antibiotic resistance gene
classes and genes listed below:
• Class A Beta lactamase





• Tetracycline ribosomal protection
• Quinolone resistance
• Macrolide/MLS resistance
• Adenosine triphosphate (ATP)-binding cassette (ABC) efflux
pump
• Resistance/nodulation/division (RND) antibiotic efflux
• Major facilitator superfamily (MFS) antibiotic efflux
• Multidrug efflux pump activity
• Multidrug resistance efflux pump
• Genes modulating antibiotic efflux: norA, baeR, marA, phoQ,
ramA, soxR
• Small multidrug resistance (SMR) antibiotic efflux
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• Chloramphenicol acetyltransferase
• Antibiotic target
• Genes modulating resistance:WblE, WhiB
• rRNA methyltransferase
• Other ARG: bacA
Probiotic Supplementation
A consensus-based protocol for probiotic supplementation was
implemented in Norway in 2014 (30). Extremely preterm infants,
contributing to around 90% of NEC cases in Norway, were
considered as the target group for probiotic prophylaxis. At this
time, probiotics was not used routinely for more mature preterm
infants (≥28 weeks gestation) in any Norwegian neonatal unit.
After considering the safety profile, a widely used probiotic
combination product was selected (Infloranr) (31). One capsule
Infloran contained 109 colony forming units (CFU) Lactobacillus
acidophilus (ATCC 4356) and 109 CFU B. longum subspecies
infantis (ATCC 15697). One-half capsule once daily was initiated
on day 3–4 and increased to one capsule daily after 4–7 days.
One capsule was opened and the content was diluted in 2ml of
breast milk, or formula. It was thereafter administered enteral via
a nasogastric tube, either 1ml (1/2 capsule) or 2ml (one capsule).
Influence of Antibiotic Therapy
To quantify changes in the gut microbiota composition and
resistome after antibiotic exposure, we stratified four different
categories of antibiotic exposure: (i) antenatal exposure, (ii)
short (≤72 h) vs. prolonged (>72 h) exposure in the first week
of life (19, 22), (iii) any exposure after first week of life
(yes/no), and (iv) narrow- vs. broad-spectrum exposure after
first week of life. Potential effects of antenatal exposure and
short vs. prolonged therapy after birth were only investigated at
7 days of age. We defined regimens including third-generation
cephalosporins or carbapenems as a broad-spectrum regimens
when compared to regimens containing aminoglycosides for
coverage against Gram-negative bacteria. This definition was
based on the fact that neonatal empiric treatment using a third-
generation cephalosporin for Gram-negative coverage induce
significantly higher antibiotic resistance rates among colonizing
bacteria than a regimen containing an aminoglycoside (32).
Ethics, Trial Registration, and Statistical
Analysis
The study was approved by the Norwegian Regional
Ethical Committee (2014/930/REK nord) and registered
in Clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/
NCT02197468). Informed written consent was obtained
from all parents.
Data were analyzed using IBM-SPSS version 22 (IBM,
Armonk NY, USA) statistical software, the R statistical
framework (version 3.2.4; http://www.r-project.org/), and
Statistical Analysis of Metagenomic Profiles (STAMP) software
package (33). We used Mann–Whitney U-test or a Kruskal–
Wallis test for comparisons between two ormultiple independent
groups. We used a Poisson generalized linear model to calculate
trends in the relative abundance of genera and ARGs in the
gut microbiota. Corrections based on multiple comparisons
were performed by the Benjamini–Hochberg false discovery rate
(FDR) (34). A FDR Q ≤ 0.10 was considered significant for any
analyses with multiple comparisons. A standard P ≤ 0.05 was
considered significant for all other analyses.
Alpha diversity was assessed by calculating the Shannon
Diversity index (MEGAN, v5.10.6) (35). To detect changes
in alpha diversity over time, we first performed a normality
test and found that the residuals were normally distributed.
Therefore, differences in alpha diversity over time between the
three different groups were calculated using linear mixed models.
The same model was used to calculate the influence of antibiotic
exposure on alpha diversity. Multiple beta diversity metrics of
samples was performed using non-metrical multidimensional
scaling (NMDS) based on a matrix of Bray-Curtis distances
calculated using the vegan R package. Differences between groups
were tested using permutational multivariate analysis on beta
diversity matrices.
RESULTS
Study Population and Antibiotic Exposure
Figure 1 shows study flow. We enrolled 66 preterm infants and
10 healthy full-term control (FTC) infants between February
and October 2015. The six study sites had different admission
numbers, and recruited each between 7 and 24 preterm infants
(Figure 1). Clinical characteristics, antibiotic and probiotic
exposure, duration of parenteral nutrition and enteral nutrition
data are reported in Table 1. The “probiotic extremely preterm
(PEP)” infants received much more antibiotics than the “non-
probiotic very preterm (NPVP)” infants after first week of life.
Two infants in the PEP-group were operated for NEC, both
survived.
Taxonomic Composition
On day 7, we found higher relative abundance of Bifidobacterium
and Lactobacillus in PEP-infants compared to NPVP-
infants (Figure 2A, Table 2). FTC infants had higher
abundance of some genera (Streptococcus, Veilonella, and
Haemophilus) that were only sparsely present in the two
preterm infant groups (Figure 2A). Mode of delivery
did not lead to detectable differences in the microbiota
composition within the preterm groups on day 7 (data not
shown).
On day 28, there was a striking increase in relative abundance
of Escherichia in the PEP-infants and a similar striking increase
in relative abundance of Bifidobacterium in NPVP-infants.
FTC infants had significantly higher relative abundance of
Lactobacillus than NPVP-infants. Overall, at 28 days of age the
FTC- and NPVP-infants had higher abundance of Veilonella and
Streptococcus than PEP-infants, while both preterm groups had
higher relative abundance of Staphylococcus and Enterococcus
than FTC-infants (Figure 2B).
By 4 months of age, there were no significant differences
in taxonomic profile between PEP- and FTC-infants. The
NPVP-infants had more Prevotella than PEP-infants, but
otherwise all three groups were similar (Figure 2C). Duration
of parenteral nutrition did not lead to detectable differences in
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FIGURE 1 | CONSORT study flow diagram. PEP, probiotic extremely preterm; NPVP, non-probiotic very preterm; FTC, full term control; NICU, Neonatal Intensive care
Unit.





Full term control (FTC)
infants
(n = 31) (n = 35) (n = 10)
Birth weight [grams], median (IQR) 835 (680–945) 1,290 (1,150–1,445) 3,613 (3,394–3,733)
Gestational age [weeks], median (IQR) 26 (26–27) 30 (29–30) 40 (40–41)
Gender
Male, n (%) 13 (42%) 20 (57%) 3 (30)
Female, n (%) 18 (58%) 15 (43%) 7 (70)
Route of delivery
Cesarean, n (%) 21 (68%) 20 (57%) 0 (0)
Vaginal, n (%) 10 (32%) 15 (43%) 10 (100)
CRIB score, mean (SD) 11 (2) 5 (2) –
Any antenatal antibiotic exposure, n (%) 8 (26%) 12 (34%) 0 (0)
Any antibiotic exposure first week of life*, n (%) 30 (97%) 27 (77%) –
Median (IQR) days—antibiotics exposed infants 6 (4–7) 4 (3–5) –
Any antibiotic exposure after first week of life, n (%) 22 (71%) 5 (14%) –
Narrow spectrum regimen after first week of life, n (%) 14 (45%) 3 (9%) –
Broad-spectrum** regimen after first week of life, n (%) 8 (26%) 2 (5%) –
Median (IQR) days antibiotics in exposed infants 6.5 (3–13) 10 (5.5–14)
Total days antibiotics, median (IQR); antibiotics exposed infants, n 9.5 (6–18) n = 30 4 (3–6) n = 27 –
Total days of probiotic supplementation, median (IQR) 46 (40–57) – –
Parenteral nutrition, n (%) 31 (100%) 16 (46%) –
Median (IQR) days parenteral nutrition 9 (6–13) 5 (3–8) –
Exclusive human milk nutrition until discharge 17 (55%) 16 (46%) 10 (100)
CRIB, Clinical Risk Index for Babies; IQR, interquartile range.
*Only ampicillin or penicillin + gentamicin were used in all preterm infants in first week of life.
**We defined regimens including third-generation cephalosporins or carbapenems as a broad-spectrum regimen.
the microbial composition between the preterm group(s) on 28
days and at 4 months of age (data not shown). We found no
differences in abundance of bifidobacteria and or lactobacilli
between hospitals at any time point.
Influence of Antibiotic Exposure on
Taxonomic Composition
We found no significant influence of antenatal antibiotic
exposure on the gut microbiota composition on day 7. However,
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FIGURE 2 | Continued
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FIGURE 2 | (A–C) Median relative abundance of dominant taxa at genus level. Box plot diagram where the inside bar represent median, the outer horizontal line of the
box represents the 25th and the 75th percentile. (A) Median relative abundance at 7 days. (B) Median relative abundance at 28 days. (C) Median relative abundance
at 4 months.
57/66 (86%) preterm infants also received antibiotic therapy
(ampicillin or penicillin + gentamicin) during the first week of
life (Table 1), limiting the possibility to detect isolated effects
of antenatal exposure. There was no difference in the gut
microbiota between those exposed to a short (≤72 h) compared
to a prolonged (>72 h) course during first week of life. Broad-
spectrum antibiotic therapy after the first week of life was
mainly given to PEP-infants. Only one child in the NPVP-group
received third generation cephalosporins after first week of life.
At 4 months of age there was reduced relative abundance of
Lactobacillus and Veilonella in those exposed to broad-spectrum
antibiotics compared to infants exposed to narrow-spectrum
therapy (Tables 3, 4). Moreover, there was a non-significant
trend toward reduced relative abundance of Bifidobacterium and
increased relative abundance of Escherichia among all preterm
infants exposed to broad-spectrum antibiotics at both 28 days
and 4 months of age (Tables 3, 4).
Diversity of the Gut Microbiota and
Influence of Antibiotic Exposure
We found large intra-individual differences in the gut
microbiota composition, in particular at 7 and 28 days of
age (Figures 2A–C). The alpha diversity increased significantly
with age in both preterm infant groups, but not in FTC-infants
(Figure 3A). FTC-infants had significant higher diversity
compared to PEP infants at 7 days of age. On day 28 and at 4
months of age, there were no significant differences in alpha
diversity between any groups. Significant overall community
(beta diversity) differences using Bray-Curtis dissimilarity were
detected comparing the three groups on infants (PEP, NPVP, and
FTC) at 7 days of age (P = 0.001) and 28 days of age (P = 0.003)
(Figures 3B–D). However, we found no difference in alpha or
beta diversity between different categories of antibiotic exposure
at the three sampling time points.
Antibiotic Resistome–Distribution of ARG
Classes and Abundance of ARGs
In all three groups, we identified putative ARGs conferring
resistance to nine different classes of antibiotics, including
beta lactams, aminoglycosides, tetracyclines, fosfomycine,
sulphonamides, vancomycin, and the macrolide-lincosamide-
streptogramin B group. Genes conferring resistance to
fluoroquinolones and chloramphenicol were only detected
in PEP- and NPVP-infants. Several genes encoding efflux pumps
were also identified at all three sampling time points. In total 99
unique ARGs were identified, of which 28 (28%) were located
on mobile genetic elements, and these latter were found in more
than 80% of all infants (Table 5).
We found 21 different genes encoding beta-lactamases,
including broad-spectrum and extended-spectrum beta
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TABLE 3 | Influence of antibiotic exposure (broad* vs. narrow) on taxonomic composition in all preterm infants (both PEP- and NPVP-infants) with fecal samples and who
received antibiotics after first week of life.
Microbiota at 28 days Microbiota at 4 months
Median relative abundance Median relative abundance
Antibiotic regimen Broad* Narrow P Broad* Narrow P FDR Q
(n = 7**) (n = 15**) (n = 9**) (n = 13**)
BACTERIAL GENERA
Bifidobacterium 14.4 28.9 0.783 14.3 41.5 0.096 0.512
Escherichia 44.5 1.40 0.368 17.4 9.9 0.209 0.669
Klebsiella 0.00 0.00 0.680 0.25 0.57 0.845 0.623
Enterobacter 0.00 0.45 0.123 0.00 0.00 0.235 0.627
Staphylococcus 0.42 0.08 0.783 0.00 0.00 1.00 1.00
Veilonella 0.00 0.00 0.945 1.25 6.01 0.001 0.016
Enterococcus 2.73 0.68 0.783 0.64 0.39 0.647 1.00
Streptococcus 0.00 0.00 0.630 0.07 0.18 0.126 0.504
Lactobacillus 0.00 0.00 0.891 0.00 0.87 0.071 0.568
PEP, probiotic extremely preterm; NPVP, non-probiotic very preterm. *We defined regimens including third-generation cephalosporins or carbapenems as a broad-spectrum regimen.
**Number of fecal samples included in these analyses.
Median relative abundance of Bacteroides, Morganella, Akkermansia, Prevotella, Acinetobacter, Haemophilus, and Serratia were <0.001 at 28 days and 4 months of age and there
were no statistical difference between groups.
Bold indicate significant difference between broad- and narrow-spectrum antibiotic exposure.
FDR, false discovery rate; only calculated for comparisons with P < 0.05.
TABLE 4 | Influence of antibiotic exposure (broad* vs. narrow) on taxonomic composition in only the PEP-infants with fecal samples and who received antibiotics after first
week of life.
Microbiota at 28 days Microbiota at 4 months
Median relative abundance Median relative abundance
Antibiotic regimen Broad* Narrow P Broad* Narrow P FDR Q
(n = 5**) (n = 12**) (n = 7**) (n = 11**)
BACTERIAL GENERA
Bifidobacterium 14.39 32.50 0.574 14.31 45.96 0.035 0.187
Escherichia 44.54 0.69 0.160 33.06 9.88 0.179 0.477
Klebsiella 0.00 0.00 0.721 0.26 0.57 1.000 1.00
Enterobacter 0.00 0.52 0.195 0.00 0.00 0.143 0.572
Staphylococcus 0.42 0.36 0.879 0.00 0.00 1.000 1.000
Veilonella 0.00 0.00 0.506 0.96 6.01 0.004 0.064
Enterococcus 2.73 0.15 0.506 0.33 0.40 0.536 0.858
Streptococcus 0.54 0.00 0.442 0.07 0.14 0.285 0.651
Lactobacillus 0.00 0.00 0.959 0.00 1.21 0.004 0.032
PEP, probiotic extremely preterm. *We defined regimens including third-generation cephalosporins or carbapenems as a broad-spectrum regimen.
**Number of fecal samples included in these analyses.
Median relative abundance of Bacteroides, Morganella, Akkermansia, Prevotella, Acinetobacter, Haemophilus, and Serratia were <0.001 at 28 days and 4 months of age and there
were no statistical difference between groups.
Bold indicate significant difference between broad- and narrow-spectrum antibiotic exposure.
FDR, false discovery rate; only calculated for comparisons with P < 0.05.
lactamases (ESBLs). ESBL-genes were represented at all
three time points in NPVP- and FTC-infants, but not detected
in PEP-infants. The methicillin resistance gene (mecA) was
identified at 7 and 28 days of age in 11/35 NPVP-infants
and 13/31 PEP-infants, but not at 4 months of age. Only
one PEP-infant and four NPVP-infants were persistent fecal
carriers of mecA at days 7 and 28. Vancomycin ARGs were
identified at 4 months of age in 16 infants, but only four of
these had received vancomycin. Many of the ARGs identified,
encoded resistance to other antibiotics than those used in the
NICUs.
On day 7 NPVP-infants had higher abundance of ARGs from
four different ARG classes and PEP-infants higher abundance
of ARGs from two other ARG classes (Table 6). Only 24% of
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FIGURE 3 | (A–D) Alpha diversity calculated by Shannon diversity index and beta diversity between PEP, NPVP, and FTC infants calculated by non-metrical
multidimensional scaling (NMDS). Box plot diagram where the inside bar represent median, the outer horizontal line of the box represents the 25th and the 75th
percentile. Error bars represent the standard error. Differences between groups at a given time point and at different time points were tested with linear mixed model.
(A) Shannon diversity index of three groups of infants at three sampling points. (B) Beta diversity (NMDS) at 7 days. (C) Beta diversity (NMDS) at 28 days. (D) Beta
diversity (NMDS) at 4 months.
TABLE 5 | Distribution of classes of antibiotic resistance genes among infants in each group.
Antibiotic group or resistance
mechanism**
7 days 28 days 4 months
PEP NPVP FTC PEP NPVP FTC PEP NPVP FTC
n = 20* n = 30* n = 10* n = 24* n = 31* n = 9* n = 24* n = 29* n = 7*
Beta lactamases 10/20 24/30 3/10 19/24 22/31 6/9 18/24 25/29 4/7
MecA gene 9/20 11/30 – 5/24 5/31 – – – –
Aminoglycoside 8/20 14/30 3/10 11/24 16/31 2/9 12/24 16/29 2/7
Tetracycline 9/20 22/30 8/10 17/24 30/31 9/9 23/24 29/29 7/7
Fluoroquinolones – 1/30 – 1/24 – – 3/24 4/29 –
Macrolides 7/20 5/30 2/10 6/24 2/31 – 2/24 – –
MLS 3/20 9/30 3/10 4/24 11/31 3/9 8/24 15/29 4/7
ABC efflux pumps 6/20 7/30 – 16/24 24/31 4/9 17/24 23/29 7/7
RND efflux pumps 7/20 12/30 2/10 12/24 18/24 4/9 12/24 19/24 5/7
Efflux pumps 3/20 3/30 8/10 2/24 4/31 2/9 6/24 8/24 3/7
Multidrug Efflux pump 9/20 14/30 1/10 11/24 7/31 1/9 – – –
Chloramphenicol 3/30 9/30 – 6/24 7/31 – 9/24 3/29 –
Fosfomycine 18/20 21/30 3/10 22/24 25/31 5/9 20/24 27/29 4/7
Sulfonamides 2/20 3/30 – 6/24 7/31 – 10/24 9/29 2/7
Antibiotic target 1/20 1/30 – 4/24 4/31 – 6/24 3/29 3/7
Antibiotic inactivation – 2/30 1/10 1/24 1/31 – 6/24 7/29 2/7
Vancomycin – – – – – – 5/24 8/29 3/7
Metronidazole – – – – – – – 1/29 –
PEP, probiotic extremely preterm; NPVP, non-probiotic very preterm; FTC, full term control.
*Number of fecal samples included in these analyses.
**See Methods for further explanation of which antibiotic resistance genes that are included in these groups.
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ARGs at 28 days ARGs at 4 months
Absolute counts/total abundance Absolute counts/total abundance
Broad* Narrow P FDR Q Broad* Narrow P FDR Q
(n = 7**) (n = 15**) (n = 9**) (n = 13**)
Class A Beta lactamase 0.00 0.00 0.447 0.731 5.00 3.01 0.324 0.864
Class C Beta lactamase 44.96 0.00 0.021 0.095 9.11 8.16 0.235 0.752
Aminoglycoside phosphotransferase 6.14 0.00 0.078 0.281 – – – –
Aminoglycoside nucleotidyltransferase 0.93 0.00 0.008 0.072 0.00 0.00 0.794 0.851
Tetracycline efflux 52.29 0.00 0.014 0.084 7.92 0.00 0.235 0.94
Tetracycline ribosomal protection 5.97 0.00 0.210 0.540 11.68 2.17 0.393 0.886
Quinolone resistance 29.75 9.43 0.298 0.671 9.40 8.34 0.357 0.816
ABC efflux pump 3.23 1.07 0.392 0.784 0.70 0.64 0.471 0.814
RND antibiotic efflux 312.10 37.73 0.875 0.875 94.00 84.96 0.393 0.63
MFS antibiotic efflux 272.36 117.02 0.490 0.68 119.50 107.51 0.404 0.59
Multidrug efflux pump activity 22.08 26.53 0.581 0.70 19.08 13.63 0.647 0.69
Multidrug resistance efflux pump 0.00 0.00 0.162 0.486 3.02 0.00 0.017 0.272
Gene modulating antibiotic efflux 75.30 15.53 0.490 0.73 19.65 20.86 0.393 0.63
SMR antibiotic efflux 0.00 0.00 0.447 0.805 – – – –
Antibiotic target 1.70 0.00 0.002 0.030 2.36 0.00 0.096 0.512
Gene modulating resistance 16.25 22.83 0.535 0.69 9.68 39.10 0.043 0.344
rRNA methyltransferase 8.59 9.07 0.581 0.65 8.41 5.56 0.601 0.67
Other ARG 24.40 12.15 0.680 0.72 7.21 7.36 0.601 0.74
*We defined regimens including third-generation cephalosporins or carbapenems as a broad-spectrum regimen.
**Number of fecal samples included in these analyses.
***See Materials and Methods section for further explanation of which antibiotic resistance genes that are included in these groups.
FDR, false discovery rate.
Bold indicates significant differences in abundance of antibiotic resistance genes between broad- and narrow-spectrum regimens (P- and Q-value).
ARG-classes changed significantly their abundance during the
three sampling points (P < 0.05) (Table 6).
On day 7 and at 4 months of age, different antibiotic exposure
did not result in significant difference in total abundance of
ARGs. However, on day 28, we detected significantly higher
abundances of four classes of ARGs, including genes encoding
beta-lactam and aminoglycoside resistance, in preterm infants
exposed to broad-spectrum antibiotics compared to infants
treated with narrow-spectrum regimens (Table 7). For the subset
of preterm infants given probiotics there were no significant
differences in abundance of ARGs at 4 weeks and 4 months
(Table 8).
DISCUSSION
The main aim of this explorative, observational multi-center
study was to obtain in-depth knowledge on how probiotics and
antibiotic therapy influenced the developing gut microbiota and
antibiotic resistome of preterm infants. Previous studies have
shown that the gut microbiota in preterm infants differs from
term infants with limited diversity and delayed acquisition of
a stable profile (36–38). However, most studies have assessed
the gut microbiota composition collapsed at higher taxonomic
rank levels (above species-genera level) by sequencing of the
16S ribosomal RNA gene (31, 39). There is limited data (21)
on the association between use of probiotics, antibiotics and gut
resistome development using shotgun-metagenomic sequencing.
Bifidobacteria strongly dominated the gut microbiota in
extremely preterm infants only few days after commencing
probiotic supplementation, in sharp contrast to very preterm
infants not receiving probiotics who predominantly had
Escherichia. High levels of probiotic bacteria are not necessarily
indicative of colonization, but may represent the passage of DNA
from the administered probiotic species through the host (40).
Still, early dominance of bifidobacteria may theoretically enhance
the risk of translocation to the blood stream, in particular during
first weeks of life in extremely preterm infants when enteral
nutrition with “fuel for bifidobacteria” is not yet fully established
(13, 14). However, bifidobacterial infections are usually mild
(14, 41), in contrast to sepsis caused by Gram-negative bacteria
(Proteobacteria), which in preterm infants are the first colonizers
of the intestinal tract. Previous studies have shown that the gut
microbiota of preterm infants shortly after birth have a high
proportion of Proteobacteria and that a bloom of Bifidobacterium
occurs first around 33 weeks of age, in line with our findings in
NPVP-infants at 7 and 28 days of age (42, 43).
Lactobacilluswas only detected in small amounts in all groups,
but relative abundance increased up to 4 months of age in all
three groups. High levels of Bifidobacterium and barely detectable
levels of Lactobacillus have been reported earlier in infants
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TABLE 8 | Influence of antibiotic exposure (broad vs. narrow after first week of life) on abundance of antibiotic resistance genes (ARGs) in probiotic supplemented




ARGs at 28 days ARGs at 4 months
Absolute counts/total abundance Absolute counts/total abundance
Broad* Narrow P FDR Q Broad* Narrow P FDR Q
(n = 5**) (n = 12**) (n = 7**) (n = 11**)
Class A Beta lactamase 0.00 0.00 0.799 0.846 1.43 3.01 0.596 0.867
Class C Beta lactamase 45.96 0.00 0.009 0.162 9.11 9.52 0.328 0.875
Aminoglycoside phosphotransferase 6.14 0.00 0.082 0.369 – – – –
Aminoglycoside nucleotidyltransferase 0.93 0.00 0.104 0.312 0.00 0.00 0.860
Tetracycline efflux 29.55 0.00 0.019 0.171 7.92 7.92 0.375 0.857
Tetracycline ribosomal protection 6.49 0.00 0.082 0.369 11.68 28.48 0.246 0.787
Quinolone resistance 29.75 7.08 0.506 0.828 9.40 9.40 0.425 0.85
ABC efflux pump 3.23 0.43 0.279 0.628 0.70 1.10 0.479 0.852
RND antibiotic efflux 312.10 19.81 0.799 0.900 94.00 93.09 0.536 0.858
MFS antibiotic efflux 272.36 79.67 0.506 0.759 70.92 111.28 0.860 0.917
Multidrug efflux pump activity 22.08 24.71 0.879 0.879 19.08 6.55 0.647 0.863
Multidrug resistance efflux pump 0.00 0.00 0.234 0.602 3.02 3.02 0.069 0.368
Gene modulating antibiotic efflux 75.30 13.81 0.328 0.656 19.65 24.88 0.008 0.128
SMR antibiotic efflux 0.00 0.00 0.506 0.759 – – – –
Antibiotic target 1.70 0.00 0.064 0.030 2.36 0.00 0.151 0.604
Gene modulating resistance 16.25 33.15 0.442 0.756 9.68 60.81 0.043 0.344
rRNA methyltransferase 5.15 6.23 0.799 0.846 8.41 2.85 0.930 0.930
Other ARG 24.40 7.31 0.506 0.700 7.21 7.21 0.724 0.891
*We defined regimens including third-generation cephalosporins or carbapenems as a broad-spectrum regimen.
**Number of fecal samples included in these analyses.
***See Materials and Methods section for further explanation of which antibiotic resistance genes that are included in these groups.
FDR, false discovery rate. Aminoglycoside acetyltransferase, Macrolide resistance genes, Chloramphenicol acetyltransferase were only present at 7 days of age.
supplemented with equal doses of a probiotic combination
of bifidobacteria and lactobacilli (31). A possible explanation
for this observation is the spatial organization of intestinal
bacteria, where lactobacilli are found in intestinal crypts, thus
less accessible when collecting luminal contents (44). Indeed, a
recent study in adults showed marked differences between the
small intestine microbiota compared to the colonic microbiota
(45), indicating the scientific limitations with fecal samples when
aiming to understand the entire human intestinal ecosystem.
There is no consensus on the optimal dose of probiotics. One
study from India compared standard and high-dose probiotic
regimens and found no difference in proportion of infants
colonized or quantitative colonization rates with probiotic
species (46). Most large randomized trial have used daily doses
of 1 × 108-109 CFU (40, 47, 48). Some authors suggest that
at least 1 × 109 CFU is required to achieve a beneficial effect,
in line with the doses used in our study (49). We observed an
early and high relative abundance of Bifidobacterium in PEP-
infants. However, we did not use traditional microbiological
methods to assess the overall bacterial abundance in the gut.
Some authors have suggested that a gradual increase in probiotic
supplementation concomitantly with increased enteral nutrition
may replicate the physiological gut microbiota development,
and secure gut growth, digestive maturation and an appropriate
response to bacterial colonization (50, 51). Our study does not
allow us to draw any conclusions on dosing. A recent study
reported that a daily dose of the same probiotic used in our study
(Infloranr) leads to significantly higher levels of Bifidobacterium
when compared to dosing bi-weekly or weekly (52).
A lower relative abundance of Bifidobacterium, Lactobacillus,
and Veilonella, and a higher relative abundance of Escherichia,
were observed at day 28 and 4 months of age among infants
treated with broad-spectrum compared to narrow-spectrum
antibiotic regimens. Reduced abundance of protective anaerobe
commensals and higher abundance of Enterobacteriaceae after
antibiotic exposure has also previously been reported (53, 54).
When comparing presence and absence of antibiotic exposure
after the first week of life, no differences in diversity or taxonomic
composition were found. Previous studies on alpha diversity
and influence of antibiotic treatment have shown inconsistent
results (55). However, infants who were most heavily exposed
to antibiotic treatment in our study were also supplemented
with probiotics. In animals, probiotics may alleviate the potential
loss of microbial diversity created by antibiotic treatment
(56). This may explain why PEP-infants, exposed to massive
antibiotic pressure, did not have reduced microbial gut diversity
compared to other groups. Thus, probiotic supplementation may
offer a protective effect partly compensating harmful effects of
antibiotics in preterm infants. However, the early low number of
taxa in preterm infant stools places constraints on interpreting
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diversity changes as diversity in a non-complex population may
reflect changes in only one taxon.
In line with others, we found that the gut antibiotic resistome
of preterm and term infants is established early, independent
of antibiotic exposure (21, 57–59). We detected significant
higher abundance of ARGs in infants receiving broad-spectrum
antibiotics compared to narrow-spectrum regimens. Gibson
and co-workers also showed that broad-spectrum antibiotic
therapy in preterm infants, was associated with enrichment of
specific ARGs (21). We aimed to investigate how probiotic
supplementation can influence the gut antibiotic resistome.
Overall, there were no differences in distribution of ARG-classes
or abundance of ARGs at 28 days and 4 months of age between
PEP-infants, exposed to massive antibiotic therapy, and the two
other groups with limited or no antibiotic exposure. One possible
mechanism for this finding is that probiotic bacteria can produce
bacteriocins that improve mucosal integrity and thereby reduces
the pathogenic bacterial population and antibiotic resistance
(60).
Strengths and Limitations
At the time of this study, probiotic supplementation to extremely
preterm infants was considered “standard of care” in Norway.
We were therefore beyond equipoise to perform a randomized
study comparing probiotic to no probiotic supplementation in
this population. The NPVP-infant group has limitations as a
control group due to maturational differences and the difference
in antibiotic exposure compared to the PEP-infants. However,
more antibiotic exposure in the PEP-infants would most likely
have led to less diversity and higher abundance of ARGs. Still,
we found few differences between the two preterm groups at
28 days and 4 months of age, suggesting a protective effect
of probiotics in the PEP-infant group. The gut microbiota
composition of preterm infants may differ between hospitals
(61), but our multi-center approach intended to average local
differences and strengthen generalizability. Infants harbor a
much lower gut microbial diversity compared to adults. Any
variation in the gut microbiota composition caused by storage
may thus theoretically have a proportionally greater effect on the
composition (25). We chose a standardized sampling technique
in order to avoid potential biases due to freezing of samples at
different time points and temperature variation during transport
to the laboratory. However, in the most immature infants the
DNA content in the early fecal samples was very low, and we were
only able to obtain sequence data from 20/31 samples at 1 week
of age.
CONCLUSION
Probiotic-supplemented extremely preterm (PEP) infants had a
high relative abundance of Bifidobacterium at 1 week of age, only
few days after start of probiotic supplementation. PEP-infants
were also exposed tomuchmore antibiotics, but overall microbial
diversity and resistome was not different than in more mature
infants at 4 weeks and 4 months. We speculate that probiotic
supplementation may induce colonization resistance and thereby
partly alleviate harmful effects of antibiotics on gut microbiota
composition and the antibiotic resistome development.
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